Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics receives Nasdaq notice over stock trading below $1.00 bid price

Negative Impact 4 of 5 legal/regulatory Written later

Akebia Therapeutics received a Nasdaq deficiency letter on October 21, 2026, because its common stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing, and the company has until April 19, 2027 to regain compliance, but it may face delisting if it does not.

Key points

  • Nasdaq notice received October 21, 2026 for closing bid price below $1.00 over 30 consecutive business days
  • Initial compliance period runs 180 calendar days, until April 19, 2027
  • Regaining compliance requires at least $1.00 closing bid for 10 consecutive business days; a second 180-day period may be possible
  • Company says it may consider a reverse stock split, but cannot assure it will regain compliance

The filing

CompanyAkebia Therapeutics, Inc. (AKBA)
Form8-K, current report
Filed with the SECOct 23, 2026, 4:06 PM ET
Accession number0001517022-26-000075

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.